Ruey-Jien Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ruey-Jien Chen has a total of 270 co-authors. Here are the top co-authors by number of shared publications:
Song-Nan Chow
18 shared publicationsS C Huang
15 shared publicationsSu-Cheng Huang
15 shared publicationsTing-Chen Chang
12 shared publications- Bor-Ching Sheu
Natl Taiwan Univ, Natl Taiwan Univ Hosp, Coll Med, Dept Obstet & Gynecol, Taipei, Taiwan
10 shared publications - Song-Nan Chow
From the Department of Obstetrics and Gynecology, National Taiwan University Hospital, and College of Medicine, Taipei, Taiwan
9 shared publications
Latest Publications
- Open Access
- 7 July 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (37) , 62081-62098
Methyltransferase G9a promotes cervical cancer angiogenesis and decreases patient survival
Methyltransferase G9a promotes cervical cancer angiogenesis and decreases patient survival Methyltransferase G9a promotes cervical cancer angiogenesis and decreases patient survival
- 7 July 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (37) , 62081-62098
Open AccessMethyltransferase G9a promotes cervical cancer angiogenesis and decreases patient survival
Methyltransferase G9a promotes cervical cancer angiogenesis and decreases patient survival Methyltransferase G9a promotes cervical cancer angiogenesis and decreases patient survival
- Open Access
- 1 November 2016
- Published by Wolters Kluwer Health in Journal of the Chinese Medical Association
- Vol. 79 (11) , 577-582
Women with endometriosis have higher comorbidities: Analysis of domestic data in Taiwan
Endometriosis, defined by the presence of viable extrauterine endometrial glands and stroma, can grow or bleed cyclically, and possesses characteristics including a destructive, invasive, and metastatic nature. Since endometriosis may result in pelvic inflammation, adhesion, chronic pain, and infertility, and can progress to biologically malignant tumors, it is a long-term major health issue in women of reproductive age. In this review, we analyze the Taiwan domestic research addressing associations between endometriosis and other diseases. Concerning malignant tumors, we identified four studies on the links between endometriosis and ovarian cancer, one on breast cancer, two on endometrial cancer, one on colorectal cancer, and one on other malignancies, as well as one on associations between endometriosis and irritable bowel syndrome, one on links with migraine headache, three on links with pelvic inflammatory diseases, four on links with infertility, four on links with obesity, four on links with chronic liver disease, four on links with rheumatoid arthritis, four on links with chronic renal disease, five on links with diabetes mellitus, and five on links with cardiovascular diseases (hypertension, hyperlipidemia, etc.). The data available to date support that women with endometriosis might be at risk of some chronic illnesses and certain malignancies, although we consider the evidence for some comorbidities to be of low quality, for example, the association between colon cancer and adenomyosis/endometriosis. We still believe that the risk of comorbidity might be higher in women with endometriosis than that we supposed before. More research is needed to determine whether women with endometriosis are really at risk of these comorbidities.
- 1 November 2016
- Published by Wolters Kluwer Health in Journal of the Chinese Medical Association
- Vol. 79 (11) , 577-582
Open AccessWomen with endometriosis have higher comorbidities: Analysis of domestic data in Taiwan
Endometriosis, defined by the presence of viable extrauterine endometrial glands and stroma, can grow or bleed cyclically, and possesses characteristics including a destructive, invasive, and metastatic nature. Since endometriosis may result in pelvic inflammation, adhesion, chronic pain, and infertility, and can progress to biologically malignant tumors, it is a long-term major health issue in women of reproductive age. In this review, we analyze the Taiwan domestic research addressing associations between endometriosis and other diseases. Concerning malignant tumors, we identified four studies on the links between endometriosis and ovarian cancer, one on breast cancer, two on endometrial cancer, one on colorectal cancer, and one on other malignancies, as well as one on associations between endometriosis and irritable bowel syndrome, one on links with migraine headache, three on links with pelvic inflammatory diseases, four on links with infertility, four on links with obesity, four on links with chronic liver disease, four on links with rheumatoid arthritis, four on links with chronic renal disease, five on links with diabetes mellitus, and five on links with cardiovascular diseases (hypertension, hyperlipidemia, etc.). The data available to date support that women with endometriosis might be at risk of some chronic illnesses and certain malignancies, although we consider the evidence for some comorbidities to be of low quality, for example, the association between colon cancer and adenomyosis/endometriosis. We still believe that the risk of comorbidity might be higher in women with endometriosis than that we supposed before. More research is needed to determine whether women with endometriosis are really at risk of these comorbidities.
- Open Access
- 1 October 2016
- Published by Elsevier in Taiwanese Journal of Obstetrics and Gynecology
- Vol. 55 (5) , 625-634
Uterine sarcoma part III—Targeted therapy: The Taiwan Association of Gynecology (TAG) systematic review
- 1 October 2016
- Published by Elsevier in Taiwanese Journal of Obstetrics and Gynecology
- Vol. 55 (5) , 625-634
Open AccessUterine sarcoma part III—Targeted therapy: The Taiwan Association of Gynecology (TAG) systematic review
- Open Access
- 1 August 2016
- Published by Elsevier in Taiwanese Journal of Obstetrics and Gynecology
- Vol. 55 (4) , 472-479
Uterine sarcoma Part II—Uterine endometrial stromal sarcoma: The TAG systematic review
- 1 August 2016
- Published by Elsevier in Taiwanese Journal of Obstetrics and Gynecology
- Vol. 55 (4) , 472-479
Open AccessUterine sarcoma Part II—Uterine endometrial stromal sarcoma: The TAG systematic review
- Open Access
- 1 August 2016
- Published by Elsevier in Taiwanese Journal of Obstetrics and Gynecology
- Vol. 55 (4) , 463-471
Uterine sarcoma Part I—Uterine leiomyosarcoma: The Topic Advisory Group systematic review
- 1 August 2016
- Published by Elsevier in Taiwanese Journal of Obstetrics and Gynecology
- Vol. 55 (4) , 463-471
Open AccessUterine sarcoma Part I—Uterine leiomyosarcoma: The Topic Advisory Group systematic review
- Open Access
- 1 December 2015
- Published by Elsevier in Taiwanese Journal of Obstetrics and Gynecology
- Vol. 54 (6) , 803-805
Highlights from the 2015 Annual Meeting and First International Congress of the Taiwan Association of Gynecology
- 1 December 2015
- Published by Elsevier in Taiwanese Journal of Obstetrics and Gynecology
- Vol. 54 (6) , 803-805
Open AccessHighlights from the 2015 Annual Meeting and First International Congress of the Taiwan Association of Gynecology
- Open Access
- 1 October 2015
- Published by Elsevier in Taiwanese Journal of Obstetrics and Gynecology
- Vol. 54 (5) , 483-488
Medical treatment for heavy menstrual bleeding
- 1 October 2015
- Published by Elsevier in Taiwanese Journal of Obstetrics and Gynecology
- Vol. 54 (5) , 483-488
Open AccessMedical treatment for heavy menstrual bleeding
- 25 March 2014
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 93 (7) , 661-668
Differential clinical characteristics, treatment response and prognosis of locally advanced adenocarcinoma/adenosquamous carcinoma and squamous cell carcinoma of cervix treated with definitive radiotherapy
Objective: To compare tumor characteristics and clinical outcome of patients with cervical locally advanced adenocarcinoma (AC)/adenosquamous carcinoma (ASC) and squamous cell carcinoma (SCC).Design: Retrospective study.Setting: National Taiwan University Hospital, Taipei, Taiwan.Population: All patients with cervical SCC (n = 35), AC or ASC (n = 194) with FIGO stage ≥IIB who received definitive radiotherapy or concurrent chemoradiotherapy (CCRT) from January 1995 to December 2009.Method: Medical and histopathological record review.Main outcome measures: Progression‐free survival (PFS), local recurrence‐free survival, distant metastasis‐free survival, and overall survival (OS).Results: Compared with the SCC subgroup, patients with AC/ASC were significantly younger (p = 0.007), more of them without clinical symptoms were diagnosed by abnormal Pap smear findings (p = 0.043), and less responded to treatment (p = 0.018). After a median follow‐up of 59.3 months, patients with AC/ASC had worse 5‐year PFS (30.0% vs. 47.6%, p = 0.044), worse 5‐year distant metastasis‐free survival (41.5% vs. 69.9%, p = 0.005), and trends toward worse 5‐year local recurrence‐free survival (64.4% vs. 76.2%, p = 0.165) and worse 5‐year OS (41.3% vs. 58.1%, p = 0.090) than patients with SCC. In univariate analysis, early FIGO stage and complete treatment response were significantly associated with PFS and OS. Histology of non‐AC/ASC and Point A biologically equivalent doses in 2‐Gy fractions >85 Gy were significantly associated with better PFS, and CCRT was significantly associated with better OS. In multivariate analysis, complete treatment response and early FIGO stage remained significant factors for predicting better PFS and OS.Conclusions: Cervical AC/ASC may be more aggressive than is SCC. For cervical AC/ASC, more comprehensively effective treatments are warranted.
- 25 March 2014
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 93 (7) , 661-668
Differential clinical characteristics, treatment response and prognosis of locally advanced adenocarcinoma/adenosquamous carcinoma and squamous cell carcinoma of cervix treated with definitive radiotherapy
Objective: To compare tumor characteristics and clinical outcome of patients with cervical locally advanced adenocarcinoma (AC)/adenosquamous carcinoma (ASC) and squamous cell carcinoma (SCC).Design: Retrospective study.Setting: National Taiwan University Hospital, Taipei, Taiwan.Population: All patients with cervical SCC (n = 35), AC or ASC (n = 194) with FIGO stage ≥IIB who received definitive radiotherapy or concurrent chemoradiotherapy (CCRT) from January 1995 to December 2009.Method: Medical and histopathological record review.Main outcome measures: Progression‐free survival (PFS), local recurrence‐free survival, distant metastasis‐free survival, and overall survival (OS).Results: Compared with the SCC subgroup, patients with AC/ASC were significantly younger (p = 0.007), more of them without clinical symptoms were diagnosed by abnormal Pap smear findings (p = 0.043), and less responded to treatment (p = 0.018). After a median follow‐up of 59.3 months, patients with AC/ASC had worse 5‐year PFS (30.0% vs. 47.6%, p = 0.044), worse 5‐year distant metastasis‐free survival (41.5% vs. 69.9%, p = 0.005), and trends toward worse 5‐year local recurrence‐free survival (64.4% vs. 76.2%, p = 0.165) and worse 5‐year OS (41.3% vs. 58.1%, p = 0.090) than patients with SCC. In univariate analysis, early FIGO stage and complete treatment response were significantly associated with PFS and OS. Histology of non‐AC/ASC and Point A biologically equivalent doses in 2‐Gy fractions >85 Gy were significantly associated with better PFS, and CCRT was significantly associated with better OS. In multivariate analysis, complete treatment response and early FIGO stage remained significant factors for predicting better PFS and OS.Conclusions: Cervical AC/ASC may be more aggressive than is SCC. For cervical AC/ASC, more comprehensively effective treatments are warranted.
- 20 June 2013
- Published by Springer Nature in Strahlentherapie und Onkologie
- Vol. 189 (8) , 675-683
MicroRNA-17-5p post-transcriptionally regulates p21 expression in irradiated betel quid chewing-related oral squamous cell carcinoma cells
Zusammenfassung Hintergrund und Ziel Das Kauen der Betelnuss ist in Taiwan mit Mundhöhlenkrebs assoziiert. OC3 ist eine orale Krebszelllinie aus Zellen eines langzeitigen Betelnusskauers, der nicht geraucht hatte. Nachdem wir herausgefunden hatten, dass MicroRNA-17-5p (miR-17-5p) in OC3-Zellen induziert wird, benutzten wir diese Zelllinie, um die biologische Rolle dieser MicroRNA bei der Reaktion auf die Ionisierungsstrahlung zu prüfen. Materialien und die Methode Eine kombinierte SYBR-green-bezogende Real-Time-PCR und ein Oligonukleotid-Ligations-Assay wurden benutzt, um die Expression des miR-17-Polycistrons in den OC3-Zellen zu prüfen. Die Rolle von miR-17-5p bzw. p21 wurde mit dem speziellen Antisense-Oligonukleotid (ODN) bewertet, das entwickelt und benutzt wurde, um deren Expression zu verhindern. Die Expression des p21-Proteins wurde mittels Western-Blot bewertet. Klonogener Assay und Annexion-V-Färbung wurden jeweils benutzt, um das Überleben und die Apoptose der Zellen zu analysieren. Zellen, in denen miR-17-5p stabil ausgeschaltet wurde, wurden für ein ekoptisches Xenotransplantat verwendet, um in vivo die Rolle des miR-17-5p zu bewerten. Ergebnisse Eine Bestrahlungsdosis von 5 Gy erhöht maßgeblich die miR-17-5p-Expression in bestrahlten OC3-Zellen. Eine Inhibition der miR-17-5p-Expression stärkt die Strahlungsempfindlichkeit der OC3-Zellen. Wir haben herausgefunden, dass miR-17-5p die strahleninduzierte p21-Expression in OC3-Zellen herunterregelt. Desweiteren haben wir mit Hilfe eines Tumor-Xenotransplantatmodells festgestellt, dass p21 eine wichtige Rolle bei der Zunahme der Strahlenempfindlichkeit der OC3-Zellen in vitro und in vivo spielt. Zusammenfassung miR-17-5p wird in bestrahlten OC3-Zellen induziert und regelt die miR-17-5p-Expression des p21-Proteins herunter, was zur Strahlenresistenz der OC3-Zellen beiträgt.
- 20 June 2013
- Published by Springer Nature in Strahlentherapie und Onkologie
- Vol. 189 (8) , 675-683
MicroRNA-17-5p post-transcriptionally regulates p21 expression in irradiated betel quid chewing-related oral squamous cell carcinoma cells
Zusammenfassung Hintergrund und Ziel Das Kauen der Betelnuss ist in Taiwan mit Mundhöhlenkrebs assoziiert. OC3 ist eine orale Krebszelllinie aus Zellen eines langzeitigen Betelnusskauers, der nicht geraucht hatte. Nachdem wir herausgefunden hatten, dass MicroRNA-17-5p (miR-17-5p) in OC3-Zellen induziert wird, benutzten wir diese Zelllinie, um die biologische Rolle dieser MicroRNA bei der Reaktion auf die Ionisierungsstrahlung zu prüfen. Materialien und die Methode Eine kombinierte SYBR-green-bezogende Real-Time-PCR und ein Oligonukleotid-Ligations-Assay wurden benutzt, um die Expression des miR-17-Polycistrons in den OC3-Zellen zu prüfen. Die Rolle von miR-17-5p bzw. p21 wurde mit dem speziellen Antisense-Oligonukleotid (ODN) bewertet, das entwickelt und benutzt wurde, um deren Expression zu verhindern. Die Expression des p21-Proteins wurde mittels Western-Blot bewertet. Klonogener Assay und Annexion-V-Färbung wurden jeweils benutzt, um das Überleben und die Apoptose der Zellen zu analysieren. Zellen, in denen miR-17-5p stabil ausgeschaltet wurde, wurden für ein ekoptisches Xenotransplantat verwendet, um in vivo die Rolle des miR-17-5p zu bewerten. Ergebnisse Eine Bestrahlungsdosis von 5 Gy erhöht maßgeblich die miR-17-5p-Expression in bestrahlten OC3-Zellen. Eine Inhibition der miR-17-5p-Expression stärkt die Strahlungsempfindlichkeit der OC3-Zellen. Wir haben herausgefunden, dass miR-17-5p die strahleninduzierte p21-Expression in OC3-Zellen herunterregelt. Desweiteren haben wir mit Hilfe eines Tumor-Xenotransplantatmodells festgestellt, dass p21 eine wichtige Rolle bei der Zunahme der Strahlenempfindlichkeit der OC3-Zellen in vitro und in vivo spielt. Zusammenfassung miR-17-5p wird in bestrahlten OC3-Zellen induziert und regelt die miR-17-5p-Expression des p21-Proteins herunter, was zur Strahlenresistenz der OC3-Zellen beiträgt.
- 1 May 2013
- Published by Wolters Kluwer Health in Menopause
- Vol. 20 (5) , 587
Letters to the Editor